Solid state forms of lumateperone ditosylate salt

Abstract

Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.

1 . Crystalline form F1 of Lumateperone ditosylate characterized by an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta±0.2 degrees two theta and an absence of a peak at: 5.7 degrees two theta±0.2 degrees two theta. 
     
     
         2 . The crystalline form of  claim 1 , wherein the XRPD pattern further has one, two, three, four or five peaks selected from: 15.4, 20.4, 21.3, 24.0 and 25.1 degrees two theta±0.2 degrees two theta. 
     
     
         3 . The crystalline form of  claim 1 , wherein the XRPD pattern further has peaks at: 15.4, 20.4, 21.3, 24.0 and 25.1 degrees two theta±0.2 degrees two theta. 
     
     
         4 . The crystalline form of  claim 1 , wherein the XRPD pattern further has an absence of one, two, three or four peaks at: 11.4, 13.4, 17.5 and 23.5 degrees two theta±0.2 degrees two theta. 
     
     
         5 . The crystalline form of  claim 1 , characterized by a solid state  13 C NMR spectrum having peaks at 142.6, 141.0, 133.8, 129.5 and 123.2 ppm±0.2 ppm. 
     
     
         6 . The crystalline form of  claim 5 , characterized by a solid state  13 C NMR spectrum having an absence of one, two, three, or four peaks selected from: 194.5, 110.2, 62.2 and 35.7 ppm±0.2 ppm. 
     
     
         7 . The crystalline form of  claim 1 , further characterized by an FT-IR spectrum having absorptions at 2617, 1632, 1480, 1280, 1210, 1163, 1104, 1004, 824 and 750 cm −1 ±2 cm −1 . 
     
     
         8 . A pharmaceutical composition comprising the crystalline form of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         9 . A method of treating one or more of: schizophrenia, bipolar disorder, depression, sleep and behavioral disturbance in dementia, autism, and other neuropsychiatric disorders, comprising administering a therapeutically effective amount of the crystalline form of  claim 1  to a patient in need thereof. 
     
     
         10 . The method of  claim 9 , wherein the crystalline form is administered in the form of a pharmaceutical composition comprising the crystalline form F1 of Lumateperone ditosylate and a pharmaceutically acceptable excipient. 
     
     
         11 . A process for preparing the crystalline form of  claim 1 , comprising:
 mixing Lumateperone and p-toluenesulfonic acid in a solvent system, the solvent system comprising methyl ethyl ketone; and   isolating the crystalline form F1 of Lumateperone ditosylate.